EU/3/16/1687: Orphan designation for the treatment of Guillain-Barré syndrome

Recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan)

Table of contents

Overview

On 27 June 2016, orphan designation (EU/3/16/1687) was granted by the European Commission to Akari Therapeutics, Plc, United Kingdom, for recombinant protein derived from the saliva of the Ornithodoros moubata tick (also known as coversin or rEV576) for the treatment of Guillain-Barré syndrome.

This medicine is now known as nomacopan.

The sponsorship was transferred to Akari Malta Limited, Malta in January 2020.

The sponsor’s address was updated in January 2022.

Key facts

Active substance
Recombinant protein derived from the saliva of the Ornithodoros moubata tick (nomacopan)
Intented use
Treatment of Guillain-Barré syndrome
Orphan designation status
Positive
EU designation number
EU/3/16/1687
Date of designation
27/06/2016
Sponsor

Akari Malta Limited, Malta
189 Marina Suites
Suite 10
Marina Street
Pieta
PTA 9041
Malta
Tel: +356 2065 0510
E-mail: info@akaritx.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating